Lineage Cell Therapeutics Stock Alpha and Beta Analysis
| LCTX Stock | USD 0.61 0.04 7.02% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Lineage Cell Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Lineage Cell over a specified time horizon. Remember, high Lineage Cell's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Lineage Cell's market risk premium analysis include:
Beta 2.04 | Alpha (0.85) | Risk 5.62 | Sharpe Ratio (0.08) | Expected Return (0.47) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Lineage |
Lineage Cell Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Lineage Cell market risk premium is the additional return an investor will receive from holding Lineage Cell long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lineage Cell. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Lineage Cell's performance over market.| α | -0.85 | β | 2.04 |
Lineage Cell expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Lineage Cell's Buy-and-hold return. Our buy-and-hold chart shows how Lineage Cell performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Lineage Cell Market Price Analysis
Market price analysis indicators help investors to evaluate how Lineage Cell stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Lineage Cell shares will generate the highest return on investment. By understating and applying Lineage Cell stock market price indicators, traders can identify Lineage Cell position entry and exit signals to maximize returns.
Lineage Cell Return and Market Media
The median price of Lineage Cell for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 0.88 with a coefficient of variation of 9.38. The daily time series for the period is distributed with a sample standard deviation of 0.08, arithmetic mean of 0.87, and mean deviation of 0.05. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 5310 shares by Hogge Gary S. of Lineage Cell at 1.35 subject to Rule 16b-3 | 09/12/2024 |
2 | OpRegen Phase 12a Results to Be Featured at International Society for Stem Cell Research 2024 Copenhagen International Symposium - StockTitan | 09/25/2024 |
3 | NovoCure Surges 10.7 percent Is This an Indication of Further Gains | 10/16/2024 |
4 | Lineage Cell Therapeutics GAAP EPS of -0.02 beats by 0.02, revenue of 3.77M beats by 2.88M | 11/14/2024 |
5 | Lineage Cell Therapeutics tumbles after pricing 66M securities offering | 11/20/2024 |
6 | Acquisition by Mulroy Michael H. of 40000 shares of Lineage Cell at 0.566 subject to Rule 16b-3 | 11/22/2024 |
About Lineage Cell Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Lineage or other stocks. Alpha measures the amount that position in Lineage Cell Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.001616 | 0.001535 | Price To Sales Ratio | 21.04 | 19.99 |
Lineage Cell Upcoming Company Events
As portrayed in its financial statements, the presentation of Lineage Cell's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lineage Cell's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Lineage Cell's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Lineage Cell. Please utilize our Beneish M Score to check the likelihood of Lineage Cell's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Lineage Cell
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.